Remove 2012 Remove Chemotherapy Remove Immunization
article thumbnail

A history of blood cancer treatment

pharmaphorum

Crucially, he observed a connection between certain tumours and inflammation, noting that neoplastic tissues were often covered with leukocytes of the immune system. 1942 – Chemotherapy moves from trenches to treatment . 1942 – Chemotherapy moves from trenches to treatment . 1907 – The magic bullet of immunotherapy.

article thumbnail

Transforming oncology with antibody therapeutics

European Pharmaceutical Review

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Overall, the mechanisms of action for amivantamab include ligand blocking, receptor degradation, and immune cell-mediated activity. 2012; 23(8): 6 – 9. Cancer Ther.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Sugemalimab plus chemo boosts lung cancer survival, trial reveals

pharmaphorum

EQRx’s GEMSTONE-302 study evaluated the efficacy and safety of the investigational anti-PD-L1 antibody, sugemalimab, in combination with chemotherapy as a first-line treatment for patients with stage four non-small cell lung cancer (NSCLC), versus using chemotherapy alone. But prevalence still increased by 10% between 2008 and 2012.

article thumbnail

Off-label Use

RX Note

External Links Understanding Unapproved Use of Approved Drugs "Off Label" Medicines for Children - Unlicensed Medicines NICE Evidence Summaries Ten Common Questions (and Their Answers) About Off-label Drug Use, 2012 Off-label medicine use: Ethics, practice and future directions, 2021

article thumbnail

CRISPR therapies targeting the next breakthrough in oncology

pharmaphorum

In 2012, Jennifer Doudna and Emmanuelle Charpentier published a paper in Science where they outlined isolating the components of the CRISPR-Cas9 system and demonstrated how it could be used to cut specific sites in isolated DNA. This would go some way to removing the damage that chemotherapy can do to healthy cells. The pipeline.

article thumbnail

Lymphoma Action – championing the patient voice in cell therapy

pharmaphorum

1 Every year, 19,500 people are diagnosed with lymphoma 2 – a cancer affecting a certain type of white blood cell within the immune system – and can be classed as either slow or fast growing. Now, people living with particular types of lymphoma have individualised options beyond chemotherapy for the first time.”. 2012, page 4.

article thumbnail

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

PharmaShots

It is the only drug in its class of chemotherapy and is developed from the natural substance found in a sea sponge. Though the exact working of Actemra in the body is not known, from early research, it is suggested that Actemra blocks the connecting of IL-6 protein to the cells and prevents overactivity of the immune system.